Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;9(10):840-854.
doi: 10.1016/j.trecan.2023.06.009. Epub 2023 Jul 11.

Advances in the treatment of metastatic prostate cancer

Georges Gebrael  1 , Gliceida Galarza Fortuna  1 , Nicolas Sayegh  1 , Umang Swami  1 , Neeraj Agarwal  2
Affiliations
Review

Advances in the treatment of metastatic prostate cancer

Georges Gebrael et al. Trends Cancer. 2023 Oct.

Abstract

The field of metastatic prostate cancer (mPCa) has seen unprecedented therapeutic advances in the past decade. In the past 2 years, recent approvals include the triplet therapy regimens of androgen deprivation therapy (ADT), docetaxel, and an androgen receptor (AR) pathway inhibitor (ARPI) in the castration-sensitive setting and lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) and the combination of poly(ADP) ribose polymerase (PARP) inhibitors (PARPis) and ARPIs in the castration-resistant setting. With many agents currently undergoing investigation in registration trials, the therapeutic armamentarium will expand rapidly, making treatment selection and sequencing challenging. Herein, we review the landmark clinical trials ongoing or reported in the past 2 years, discuss the optimal approach to treatment selection, and provide insight into future directions.

Keywords: ARPIs; PARP inhibitors; metastatic castration-resistant prostate cancer; metastatic castration-sensitive prostate cancer; novel hormonal therapy; treatment.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests N.A. reports consultancy (lifetime association) to Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics and reports institutional research funding from AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, GlaxoSmithKline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. U.S. reports consultancy to Astellas, Exelixis, Seattle Genetics, Imvax, AstraZeneca, and Sanofi and research funding to institute from Janssen, Exelixis, and Astellas/Seattle Genetics.

MeSH terms

LinkOut - more resources